Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

229
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
229
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

8.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

967
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
967
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Structure and Function of Platelets01:18

Structure and Function of Platelets

2.7K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of complete blood count (CBC) parameters in patients with Sanjad-sakati syndrome and healthy controls in Abuzar Hospital, Ahvaz.

European journal of pediatrics·2026
Same author

Altered inflammatory and coagulation markers in women with a history of recurrent pregnancy loss: A case-control study.

International journal of reproductive biomedicine·2026
Same author

Frequency and Demographic Patterns of SARS-CoV-2 and Influenza Virus Infections in Khuzestan: A Retrospective Observational Study (2021-2023).

Advances in virology·2026
Same author

Investigating subclinical myocardial ischemia by measuring carotid intima-media thickness using Doppler Ultrasound in patients with acute cardiac ischemia.

Caspian journal of internal medicine·2026
Same author

Potential Effects of Aspirin on Transcription Factors Related to the Inflammation in Atherosclerosis: A Systematic Review.

Health science reports·2026
Same author

The role of chemokine receptors in leukemia: implications for prognosis and therapeutic strategies.

Molecular biology reports·2026

Related Experiment Video

Updated: Dec 25, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K

Platelet Activation Polymorphisms in Ischemia.

Habib Haybar1, Elahe Khodadi2, Kazem Zibara3

  • 1Atherosclerosis Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Cardiovascular & Hematological Disorders Drug Targets
|March 27, 2018
PubMed
Summary
This summary is machine-generated.

Genetic variations in platelets significantly impact ischemia risk and treatment response. Identifying these platelet polymorphisms aids in predicting patient outcomes and tailoring therapies for ischemia.

Keywords:
Plateletatherosclerotic plaquecardiovasculardiabetesglycoproteinsischemiaobesitypolymorphisms.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

944
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K

Related Experiment Videos

Last Updated: Dec 25, 2025

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.2K
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

944
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

22.8K

Area of Science:

  • Cardiovascular Genetics
  • Hematology
  • Medical Genetics

Background:

  • Ischemia is a complex disorder influenced by genetic and environmental factors.
  • Platelets play a key role in ischemia, with elevated activity and aggregation increasing risks of atherosclerosis and thrombosis.
  • Genetic polymorphisms in platelet receptors and other genes contribute to platelet dysfunction and ischemia development.

Purpose of the Study:

  • To review the role of genetic polymorphisms in platelet activation.
  • To evaluate the contribution of these polymorphisms to the development of ischemia.

Main Methods:

  • Literature review of studies on platelet polymorphisms and ischemia.
  • Analysis of genetic variations affecting platelet function and their association with ischemic events.

Main Results:

  • Specific polymorphisms in platelet receptors are linked to increased ischemia risk.
  • Variations in other genes also influence platelet adhesion and aggregation, contributing to ischemia.
  • Patient response to anti-platelet drugs is affected by polymorphisms, potentially causing drug resistance.

Conclusions:

  • Genetic polymorphisms in platelets are crucial factors in ischemia pathogenesis.
  • Understanding these polymorphisms can improve prognosis prediction and guide personalized anti-platelet therapy for ischemia patients.